A highly efficient, metal-free, chemical oxidation of hydrazines has been implemented using environmentally friendly TCCA as oxidant. This benign protocol provides straightforward access to a wide range of azo compounds in THF in excellent yield. Altogether, 35 azo compounds were obtained in this way and scale-up preparations were performed. Additionally, a plausible mechanism was also proposed. Step-economical
Convenient semihydrogenation of azoarenes to hydrazoarenes using H<sub>2</sub>
作者:Manoj K. Sahoo、Ganesan Sivakumar、Sanjay Jadhav、Samrin Shaikh、Ekambaram Balaraman
DOI:10.1039/d1ob00850a
日期:——
The high atom-economical and eco-benign nature of hydrogenation reactions make them much more superior to conventional reduction and transferhydrogenation. Herein, a convenient and highly selective hydrogenation reaction of azoarenes using molecular hydrogen to access diverse hydrazoarenes is reported. The present catalytic method is general and operationally simple, and it operates under exceedingly
hydrazoarenes using ethanol as a hydrogen source by a bidentate Ru(II)-NC complex is developed. A weak base is crucial for this semihydrogenation that can efficiently avoid hydrazoarene dehydrogenation under strongly basic conditions. Control experiments and density functional theory calculations demonstrate the mechanism via a Meerwein–Ponndorf–Verley mechanism, and the only byproduct is ethylacetate. This study
申请人:THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICE
公开号:US10703746B2
公开(公告)日:2020-07-07
Compounds of Formula I and Formula II and the pharmaceutically acceptable salts thereof are disclosed The variables A, B, Y, Z, X1, X2, R1-4 and R13-18 are disclosed herein. The compounds are useful for treating cancer disorders, especially those involving mutant IDH1 enzymes. Pharmaceutical compositions containing compounds of Formula I or Formula II and methods of treatment comprising administering compounds of Formula I and Formula II are also disclosed.
公开了式 I 和式 II 的化合物及其药学上可接受的盐 本文公开了变量 A、B、Y、Z、X1、X2、R1-4 和 R13-18。这些化合物可用于治疗癌症疾病,特别是涉及突变 IDH1 酶的疾病。还公开了含有式 I 或式 II 化合物的药物组合物以及包括施用式 I 和式 II 化合物的治疗方法。
Cobalt-Catalyzed Borylative Reduction of Azobenzenes to Hydrazobenzenes via a Diborylated-Hydrazine Intermediate
Cobalt-catalyzed borylative reduction of azobenzenes using pinacolborane is developed. The simple cobalt chloride catalyst and reaction conditions make this protocol attractive for hydrazobenzene synthesis. This borylative reduction shows good functional group compatibility and can be readily scaled up to the gram scale. Preliminary mechanistic studies clarified the proton source of the hydrazine products